1
|
Liu H, Ji M, Xiao P, Gou J, Yin T, He H, Tang X, Zhang Y. Glucocorticoids-based prodrug design: Current strategies and research progress. Asian J Pharm Sci 2024; 19:100922. [PMID: 38966286 PMCID: PMC11222810 DOI: 10.1016/j.ajps.2024.100922] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 02/04/2024] [Accepted: 03/06/2024] [Indexed: 07/06/2024] Open
Abstract
Attributing to their broad pharmacological effects encompassing anti-inflammation, antitoxin, and immunosuppression, glucocorticoids (GCs) are extensively utilized in the clinic for the treatment of diverse diseases such as lupus erythematosus, nephritis, arthritis, ulcerative colitis, asthma, keratitis, macular edema, and leukemia. However, long-term use often causes undesirable side effects, including metabolic disorders-induced Cushing's syndrome (buffalo back, full moon face, hyperglycemia, etc.), osteoporosis, aggravated infection, psychosis, glaucoma, and cataract. These notorious side effects seriously compromise patients' quality of life, especially in patients with chronic diseases. Therefore, glucocorticoid-based advanced drug delivery systems for reducing adverse effects have received extensive attention. Among them, prodrugs have the advantages of low investment, low risk, and high success rate, making them a promising strategy. In this review, we propose the strategies for the design and summarize current research progress of glucocorticoid-based prodrugs in recent decades, including polymer-based prodrugs, dendrimer-based prodrugs, antibody-drug conjugates, peptide-drug conjugates, carbohydrate-based prodrugs, aliphatic acid-based prodrugs and so on. Besides, we also raise issues that need to be focused on during the development of glucocorticoid-based prodrugs. This review is expected to be helpful for the research and development of novel GCs and prodrugs.
Collapse
Affiliation(s)
- Hongbing Liu
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Muse Ji
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Peifu Xiao
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Jingxin Gou
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Tian Yin
- School of Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Haibing He
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Xing Tang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| | - Yu Zhang
- Department of Pharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China
| |
Collapse
|
2
|
Applegate CC, Deng H, Kleszynski BL, Cross TWL, Konopka CJ, Dobrucki LW, Nelson ER, Wallig MA, Smith AM, Swanson KS. Impact of administration route on nanocarrier biodistribution in a murine colitis model. JOURNAL OF EXPERIMENTAL NANOSCIENCE 2022; 17:599-616. [PMID: 36968097 PMCID: PMC10038121 DOI: 10.1080/17458080.2022.2134563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 09/08/2022] [Accepted: 09/08/2022] [Indexed: 06/18/2023]
Abstract
The incidence of inflammatory bowel disease (IBD) is increasing worldwide. Although current diagnostic and disease monitoring tests for IBD sensitively detect gut inflammation, they lack the molecular and cellular specificity of positron emission tomography (PET). In this proof-of-concept study, we use a radiolabeled macrophage-targeted nanocarrier probe (64Cu-NOTA-D500) administered by oral, enema, and intraperitoneal routes to evaluate the delivery route dependence of biodistribution across healthy and diseased tissues in a murine model of dextran sodium sulfate (DSS)-induced colitis. High inter-subject variability of probe uptake in intestinal tissue was reduced by normalization to uptake in liver or total intestines. Differences in normalized uptake between healthy and DSS colitis animal intestines were highest for oral and IP routes. Differences in absolute liver uptake reflected a possible secondary diagnostic metric of IBD pathology. These results should inform the preclinical development of inflammation-targeted contrast agents for IBD and related gut disorders to improve diagnostic accuracy.
Collapse
Affiliation(s)
- Catherine C. Applegate
- Division of Nutritional Sciences, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Department of Animal Sciences, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Hongping Deng
- Department of Bioengineering, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Brittany L. Kleszynski
- Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Tzu-Wen L. Cross
- Department of Nutrition Science, Purdue University, West Lafayette, Indiana, USA
| | | | - L. Wawrzyniec Dobrucki
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Cancer Center at Illinois, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Erik R. Nelson
- Division of Nutritional Sciences, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA
- Cancer Center at Illinois, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Department of Molecular and Integrative Physiology, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA
- Carl R. Woese Institute for Genomic Biology, Anticancer Discovery from Pets to People Theme, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Matthew A. Wallig
- Division of Nutritional Sciences, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Department of Pathobiology, College of Veterinary Medicine, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Andrew M. Smith
- Department of Bioengineering, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Cancer Center at Illinois, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Carle Illinois College of Medicine, Urbana, Illinois, USA
- Micro and Nanotechnology Laboratory, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Department of Materials Science and Engineering, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| | - Kelly S. Swanson
- Division of Nutritional Sciences, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
- Department of Animal Sciences, University of Illinois at Urbana – Champaign, Urbana, Illinois, USA
| |
Collapse
|
3
|
Coyne CP, Narayanan L. Carnosic Acid, Tangeretin, and Ginkgolide-B Anti-neoplastic Cytotoxicity in Dual Combination with Dexamethasone-[anti-EGFR] in Pulmonary Adenocarcinoma (A549). Anticancer Agents Med Chem 2019; 19:802-819. [DOI: 10.2174/1871520619666181204100226] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2017] [Revised: 06/06/2018] [Accepted: 10/08/2018] [Indexed: 12/18/2022]
Abstract
Background:Traditional chemotherapeutics of low-molecular weight diffuse passively across intact membrane structures of normal healthy cells found in tissues and organ systems in a non-specific unrestricted manner which largely accounts for the induction of most sequelae which restrict dosage, administration frequency, and duration of therapeutic intervention. Molecular strategies that offer enhanced levels of potency, greater efficacy and broader margins-of-safety include the discovery of alternative candidate therapeutics and development of methodologies capable of mediating properties of selective “targeted” delivery.Materials and Methods:The covalent immunopharmaceutical, dexamethasone-(C21-phosphoramidate)-[anti- EGFR] was synthesized utilizing organic chemistry reactions that comprised a multi-stage synthesis regimen. Multiple forms of analysis were implemented to vadliate the successful synthesis (UV spectrophotometric absorbance), purity and molar-incorporation-index (UV spectrophotometric absorbance, chemical-based protein determination), absence of fragmentation/polymerization (SDS-PAGE/chemiluminescent autoradiography), retained selective binding-avidity of IgG-immunoglobulin (cell-ELISA); and selectively “targeted” antineoplastic cytotoxicity (biochemistry-based cell vitality/viability assay).Results:The botanicals carnosic acid, ginkgolide-B and tangeretin, each individually exerted maximum antineoplastic cytotoxicity levels of 58.1%, 5.3%, and 41.1% respectively against pulmonary adenocarcinoma (A549) populations. Dexamethasone-(C21-phosphoramidate)-[anti-EGFR] formulated at corticosteroid/ glucocorticoid equivalent concentrations produced anti-neoplastic cytotoxicity at levels of 7.7% (10-9 M), 26.9% (10-8 M), 64.9% (10-7 M), 69.9% (10-6 M) and 73.0% (10-5 M). Ccarnosic acid, ginkgolide-B and tangeretin in simultaneous dual-combination with dexamethasone-(C21-phosphoramidate)-[anti-EGFR] exerted maximum anti-neoplastic cytotoxicity levels of 70.5%, 58.6%, and 69.7% respectively.Discussion:Carnosic acid, ginkgolide-B and tangeretin botanicals exerted anti-neoplastic cytotoxicity against pulmonary adenocarcinoma (A549) which additively contributed to the anti-neoplastic cytotoxic potency of the covalent immunopharmaceutical, dexamethasone-(C21-phosphoramidate)-[anti-EGFR]. Carnosic acid and tangeretin were most potent in this regard both individually and in dual-combination with dexamethasone-(C21- phosphoramidate)-[anti-EGFR]. Advantages and attributes of carnosic acid and tangeretin as potential monotherapeutics are a wider margin-of-safety of conventional chemotherapeutics which would readily complement the selective “targeted” delivery properties of dexamethasone-(C21-phosphoramidate)-[anti-EGFR] and possibly other covalent immunopharmaceuticals in addition to providing opportunities for the discovery of combination therapies that provide heightened levels of anti-neoplastic efficacy.
Collapse
Affiliation(s)
- Cody P. Coyne
- Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi 39762, United States
| | - Lakshmi Narayanan
- Department of Basic Sciences, College of Veterinary Medicine at Wise Center, Mississippi State University, Mississippi 39762, United States
| |
Collapse
|
4
|
Waters RC, Hochhaus G. Characterization of a dextran-budesonide prodrug for inhalation therapy. Eur J Pharm Sci 2018; 129:58-67. [PMID: 30521945 DOI: 10.1016/j.ejps.2018.11.038] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 10/20/2018] [Accepted: 11/29/2018] [Indexed: 11/19/2022]
Abstract
Reducing the dosing frequency of corticosteroids may increase compliance and increase pulmonary targeting. The objective of this study was to evaluate whether a high molecular weight dextran-budesonide conjugate might be suitable for pulmonary slow release of the otherwise fast absorbed budesonide. An array of dextran-spacer-budesonide conjugates was prepared that differed in the molecular weight of dextran (20 kDa or 40 kDa) and the length of the dicarboxylic spacer (succinic, glutaric, and adipic anhydride). The conjugates were characterized for identity by proton nuclear magnetic resonance (1H NMR) and Fourier-transform infrared spectroscopy (FTIR), the degree of dextran-hydroxyl conjugation, purity, and physiological activation (release of budesonide). The 40 kDa dextran-succinate-budesonide conjugate was formulated as a dry powder for pulmonary delivery and characterized for particle size distribution, particle morphology, and aerodynamic particle size. The degree of substitution (grams of budesonide in 100 g of conjugate) ranged from 4 to 10% for all six dextran-spacer-budesonide conjugates. Incubation at 37 °C and pH 7.4 in phosphate buffered saline resulted in release of 25-75% of the conjugated budesonide over an 8-hour period with the rate of release increasing with molecular weight of dextran and the length of the spacer. Modeling of the concentration time profiles of the released budesonide and budesonide-21-hemisucinate in phosphate buffered saline, suggested that budesonide is generated either directly or via the budesonide-21-hemisucinate pre-cursor. Data also suggested that the rate of budesonide generation likely depends on the position of budesonide on the dextran molecule. Spray-drying the 40 kDa dextran-succinate-budesonide produced respirable particles of the conjugate with a mass median aerodynamic particle size (MMAD) of 4 μm. The slow generation of budesonide from the chemical delivery system might further improve the pharmacological profile of budesonide.
Collapse
Affiliation(s)
- Robert C Waters
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States of America
| | - Günther Hochhaus
- Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, United States of America.
| |
Collapse
|
5
|
Coyne CP, Narayanan L. Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549). Drug Des Devel Ther 2016; 10:2575-97. [PMID: 27574398 PMCID: PMC4990379 DOI: 10.2147/dddt.s102075] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
PURPOSE Corticosteroids are effective in the management of a variety of disease states, such as several forms of neoplasia (leukemia and lymphoma), autoimmune conditions, and severe inflammatory responses. Molecular strategies that selectively "target" delivery of corticosteroids minimize or prevents large amounts of the pharmaceutical moiety from passively diffusing into normal healthy cell populations residing within tissues and organ systems. MATERIALS AND METHODS The covalent immunopharmaceutical, dexamethasone-(C21-phosphoramide)-[anti-EGFR] was synthesized by reacting dexamethasone-21-monophosphate with a carbodiimide reagent to form a dexamethasone phosphate carbodiimide ester that was subsequently reacted with imidazole to create an amine-reactive dexamethasone-(C21-phosphorylimidazolide) intermediate. Monoclonal anti-EGFR immunoglobulin was combined with the amine-reactive dexamethasone-(C21-phosphorylimidazolide) intermediate, resulting in the synthesis of the covalent immunopharmaceutical, dexamethasone-(C21-phosphoramide)-[anti-EGFR]. Following spectrophotometric analysis and validation of retained epidermal growth factor receptor type 1 (EGFR)-binding avidity by cell-ELISA, the selective anti-neoplasic cytotoxic potency of dexamethasone-(C21-phosphoramide)-[anti-EGFR] was established by MTT-based vitality stain methodology using adherent monolayer populations of human pulmonary adenocarcinoma (A549) known to overexpress the tropic membrane receptors EGFR and insulin-like growth factor receptor type 1. RESULTS The dexamethasone:IgG molar-incorporation-index for dexamethasone-(C21-phosphoramide)-[anti-EGFR] was 6.95:1 following exhaustive serial microfiltration. Cytotoxicity analysis: covalent bonding of dexamethasone to monoclonal anti-EGFR immunoglobulin did not significantly modify the ex vivo antineoplastic cytotoxicity of dexamethasone against pulmonary adenocarcinoma at and between the standardized dexamethasone equivalent concentrations of 10(-9) M and 10(-5) M. Rapid increases in antineoplastic cytotoxicity were observed at and between the dexamethasone equivalent concentrations of 10(-9) M and 10(-7) M where cancer cell death increased from 7.7% to a maximum of 64.9% (92.3%-35.1% residual survival), respectively, which closely paralleled values for "free" noncovalently bound dexamethasone. DISCUSSION Organic chemistry reaction regimens were optimized to develop a multiphase synthesis regimen for dexamethasone-(C21-phosphoramide)-[anti-EGFR]. Attributes of dexamethasone-(C21-phosphoramide)-[anti-EGFR] include a high dexamethasone molar incorporation-index, lack of extraneous chemical group introduction, retained EGFR-binding avidity ("targeted" delivery properties), and potential to enhance long-term pharmaceutical moiety effectiveness.
Collapse
Affiliation(s)
| | - Lakshmi Narayanan
- Department of Clinical Sciences, College of Veterinary Medicine, Mississippi State University, Starkville, MS, USA
| |
Collapse
|
6
|
Ma L, Liu TW, Wallig MA, Dobrucki IT, Dobrucki LW, Nelson ER, Swanson KS, Smith AM. Efficient Targeting of Adipose Tissue Macrophages in Obesity with Polysaccharide Nanocarriers. ACS NANO 2016; 10:6952-62. [PMID: 27281538 DOI: 10.1021/acsnano.6b02878] [Citation(s) in RCA: 72] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
Obesity leads to an increased risk for type 2 diabetes, heart disease, stroke, and cancer. The causal link between obesity and these pathologies has recently been identified as chronic low-grade systemic inflammation initiated by pro-inflammatory macrophages in visceral adipose tissue. Current medications based on small-molecule drugs yield significant off-target side effects with long-term use, and therefore there is a major need for targeted therapies. Here we report that nanoscale polysaccharides based on biocompatible glucose polymers can efficiently target adipose macrophages in obese mice. We synthesized a series of dextran conjugates with tunable size linked to contrast agents for positron emission tomography, fluorophores for optical microscopy, and anti-inflammatory drugs for therapeutic modulation of macrophage phenotype. We observed that larger conjugates efficiently distribute to visceral adipose tissue and selectively associate with macrophages after regional peritoneal administration. Up to 63% of the injected dose remained in visceral adipose tissue 24 h after administration, resulting in >2-fold higher local concentration compared to liver, the dominant site of uptake for most nanomedicines. Furthermore, a single-dose treatment of anti-inflammatory conjugates significantly reduced pro-inflammatory markers in adipose tissue of obese mice. Importantly, all components of these therapeutic agents are approved for clinical use. This work provides a promising nanomaterials-based delivery strategy to inhibit critical factors leading to obesity comorbidities and demonstrates a unique transport mechanism for drug delivery to visceral tissues. This approach may be further applied for high-efficiency targeting of other inflammatory diseases of visceral organs.
Collapse
Affiliation(s)
- Liang Ma
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Tzu-Wen Liu
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Matthew A Wallig
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Iwona T Dobrucki
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Lawrence W Dobrucki
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Erik R Nelson
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Kelly S Swanson
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| | - Andrew M Smith
- Department of Materials Science and Engineering, ‡Micro and Nanotechnology Laboratory, §Division of Nutritional Sciences, ∥Department of Pathobiology, ⊥Beckman Institute for Advanced Science and Technology, #Department of Bioengineering, □Department of Molecular and Integrative Physiology and University of Illinois Cancer Center, and ⬡Department of Animal Sciences, University of Illinois at Urbana-Champaign , Urbana, Illinois 61801, United States
| |
Collapse
|
7
|
Dheer D, Arora D, Jaglan S, Rawal RK, Shankar R. Polysaccharides based nanomaterials for targeted anti-cancer drug delivery. J Drug Target 2016; 25:1-16. [DOI: 10.3109/1061186x.2016.1172589] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
8
|
Shrivastava PK, Shrivastava A, Sinha SK, Shrivastava SK. Dextran Carrier Macromolecules for Colon-specific Delivery of 5-Aminosalicylic Acid. Indian J Pharm Sci 2013; 75:277-83. [PMID: 24082343 PMCID: PMC3783745 DOI: 10.4103/0250-474x.117420] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2012] [Revised: 03/03/2013] [Accepted: 03/13/2013] [Indexed: 11/30/2022] Open
Abstract
Present manuscript describes the sustained and targeted delivery of 5-aminosalicylic acid to the distal ileum and proximal colon, using dextran (40 kDa) as a carrier for targeting 5-aminosalicylic acid at the colonic site by attaching p-aminobenzoic acid and benzoic acid as linkers. Prepared conjugate were characterized by UV, HPLC, FT-IR, and 1H NMR. The degree of substitution was estimated by complete hydrolysis of conjugates in borate buffer and in vitro hydrolysis study of conjugates was performed in different biological media. It was observed that 5-aminosalicylic acid alone have produced high incidence of gastric ulcer with high ulcer index whereas lower ulcer index was found for the dextran conjugates of 5-aminosalicylic acid. The release pattern of conjugates in 3% w/v rat caecal content was confirmed the colon specificity of 5-aminosalicylic acid conjugates.
Collapse
Affiliation(s)
- P K Shrivastava
- Pharmaceutical Chemistry Research Laboratory, Department of Pharmaceutics, Indian Institute of Technology, Banaras Hindu University, Varanasi-221 005, India
| | | | | | | |
Collapse
|
9
|
|
10
|
Dhanaraju MD, Elizabeth S, Gunasekaran T. Triamcinolone-loaded glutaraldehyde cross-linked chitosan microspheres: Prolonged release approach for the treatment of rheumatoid arthritis. Drug Deliv 2010; 18:198-207. [DOI: 10.3109/10717544.2010.528069] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Varshosaz J, Emami J, Ahmadi F, Tavakoli N, Minaiyan M, Fassihi A, Mahzouni P, Dorkoosh F. Preparation of budesonide–dextran conjugates using glutarate spacer as a colon-targeted drug delivery system:in vitro/in vivoevaluation in induced ulcerative colitis. J Drug Target 2010; 19:140-53. [DOI: 10.3109/10611861003801826] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
12
|
Nangrejo M, Ahmad Z, Stride E, Edirisinghe M, Colombo P. Preparation of polymeric and ceramic porous capsules by a novel electrohydrodynamic process. Pharm Dev Technol 2008; 13:425-32. [PMID: 18720243 DOI: 10.1080/10837450802247929] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
The preparation of capsules for medical and industrial use can be achieved via several conventional routes, yielding either hard or soft receptacles, depending on the type and the content of the material to be encapsulated. Together with tablets, capsules are amongst the most commonly used means of administering medication and this makes progress in capsule preparation technology a key area of drug delivery research. Here we uncover new technology for the preparation of capsules with porous chambers. The novelty is signified in the use of an electrohydrodynamic process engineering route and its potential is elucidated using a polymeric material; polymethylsilsesquioxane, which can be converted into an identical ceramic form by means of simple pyrolysis. Thus, both polymeric and ceramic capsules have been prepared. The effects of process control parameters such as the applied voltage and flow rate, on the characteristics of the capsules prepared are discussed.
Collapse
Affiliation(s)
- M Nangrejo
- Department of Mechanical Engineering, University College London, London, UK
| | | | | | | | | |
Collapse
|
13
|
Yeagy BA, Prudencio A, Schmeltzer RC, Uhrich KE, Cook TJ. Characterization andin vitrodegradation of salicylate-derived poly(anhydride-ester microspheres). J Microencapsul 2008; 23:643-53. [PMID: 17118880 DOI: 10.1080/02652040600776481] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The aim of this study was to investigate how glass transition temperature (Tg) influenced polymer microsphere formation and degradation of three chemically, similar novel salicylatebased poly(anhydride-esters): poly[1,6-bis(o-carboxyphenoxy)hexanoate] (CPH), Tg = 59 degrees C; poly[1,8-bis(o-carboxyphenoxy)octanoate] (CPO), Tg = 30 degrees C; and poly[1,10-bis(ocarboxyphenoxy) decanoate] (CPD), Tg = 27 degrees C. Microspheres of these polymers were prepared using a modified oil-in-water solvent evaporation method and processed by either resuspension or washed by centrifugation. The morphology of the microspheres determined by scanning electron microscopy (SEM) revealed that an extra washing step appears to increase aggregation as the Tg decreases; whereas only limited aggregation occurred in the polymer with the lowest Tg, CPD, in those not washed by centrifugation. Residual polyvinyl alcohol apparently affected the drug release rates from the microspheres by a stabilization process that produced an 8 h lag time and a 5% decrease in the amount of drug released over a 7 day period compared to microspheres washed free of PVA. These results demonstrate that salicylate-based poly(anhydride-esters) with sufficiently high Tgs, can be processed into microspheres that release salicylate over a time period amenable for drug delivery applications.
Collapse
Affiliation(s)
- Brian A Yeagy
- Department of Pharmaceutics, The State University of New Jersey, Piscataway, NJ 08854, USA
| | | | | | | | | |
Collapse
|
14
|
Hao AJ, Deng YJ, Li TF, Suo XB, Cao YH, Hao YL, Zhang Y. Degradation Kinetics of Fluorouracil-Acetic-Acid-Dextran Conjugate in Aqueous Solution. Drug Dev Ind Pharm 2008; 32:757-63. [PMID: 16885130 DOI: 10.1080/03639040600683436] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
The degradation kinetics of fluorouracil-acetic-acid-dextran conjugate (FUAC-dextran) was investigated in various buffer solutions with different pH value and physiological saline solution at 60 degrees C and 37 degrees C, respectively. The hydrolytic reaction displayed pseudo-first-order degradation kinetics. Hydrolytic rate constant obtained was the function of pH value and independent of species of buffering agents. The smallest rate constant was observed at pH round 3.00. The activation energy of the hydrolytic reaction was estimated from Arrhenius equation as 88.73 +/- 6.00 kJ.mol-1. The special base catalytic degradation of the conjugate was observed from acidic to slight alkaline condition and the special base catalytic rate constants were calculated. The conjugate was more stable in physiological saline than that in buffer solution at pH 7.00 or 9.00 at 37 degrees C. The results revealed that the conjugate was stable in acidic condition and will degrade in alkaline condition.
Collapse
Affiliation(s)
- A J Hao
- Shenyang Pharmaceutical University, Shenyang City, Liaoning Province, P.R. China
| | | | | | | | | | | | | |
Collapse
|
15
|
SAKURAI M, OZEKI Y, ANDO M, OKAMOTO H, DANJO K. Drug Delivery to the Colon Using a Novel One-Step Dry-Coated Tablets (OSDrC). YAKUGAKU ZASSHI 2008; 128:951-7. [DOI: 10.1248/yakushi.128.951] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
| | | | - Masaki ANDO
- OSDrC Division, Sanwa Kagaku Kenkyusho Co., Ltd
| | | | | |
Collapse
|
16
|
SAKURAI M, OZEKI Y, ANDO M, OKAMOTO H, DANJO K. Preparation and Release Profile of Colon-Targeting Drug Delivered as Novel One-Step Dry-Coated Tablets (OSDrC ®). YAKUGAKU ZASSHI 2007; 127:2057-63. [DOI: 10.1248/yakushi.127.2057] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
| | | | - Masaki ANDO
- OSDrC Division, Sanwa Kagaku Kenkyusho Co., Ltd
| | | | | |
Collapse
|
17
|
Nuttelman CR, Tripodi MC, Anseth KS. Dexamethasone-functionalized gels induce osteogenic differentiation of encapsulated hMSCs. J Biomed Mater Res A 2006; 76:183-95. [PMID: 16265650 DOI: 10.1002/jbm.a.30537] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Synthetic hydrogels represent highly controlled environments for three-dimensional culture of human mesenchymal stem cells (hMSCs). Encapsulated hMSCs are presented with a "blank" environment, and this environment can be closely controlled in order to elicit an osteogenic response. In vitro, dexamethasone is an efficient and reliable factor that leads to the osteogenic differentiation of human mesenchymal stem cells (hMSCs). The aim of this work was to develop a dexamethasone-releasing poly(ethylene glycol) (PEG)-based hydrogel scaffold to deliver dexamethasone to encapsulated cells in a sustained manner. To accomplish this goal, dexamethasone was covalently linked to a photoreactive mono-acrylated PEG molecule through a degradable lactide bond, and this molecule was covalently incorporated into the PEG hydrogel during photopolymerization. Over time, hydrolysis of the ester bonds resulted in dexamethasone release from the gel. The biological activity of the released dexamethasone was verified in monolayer cell culture and in three-dimensional culture (i.e., in the gel) by the ability of hMSCs to express osteogenic genes, including alkaline phosphatase, osteopontin, and core binding factor alpha 1, as measured using real-time reverse transcription polymerase chain reaction (RT-PCR). These studies indicate that encapsulated hMSCs are capable of osteogenic differentiation in response to released dexamethasone.
Collapse
Affiliation(s)
- Charles R Nuttelman
- Department of Chemical and Biological Engineering, University of Colorado, Boulder, Colorado 80309-0424, USA
| | | | | |
Collapse
|
18
|
Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv Drug Deliv Rev 2004; 56:491-509. [PMID: 14969755 DOI: 10.1016/j.addr.2003.10.017] [Citation(s) in RCA: 144] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2003] [Accepted: 10/14/2003] [Indexed: 12/14/2022]
Abstract
Targeting of drugs to specific sites of action provides several advantages over non-targeted drugs. These include the prevention of side effects of drugs on healthy tissues and enhancement of drug uptake by targeted cells. This review will cover traditional approaches of colon drug targeting as well as the use of lectins and neoglycoconjugates for the targeted delivery. Direct and reverse targeting strategies, potential molecular targets and targeting moieties for colon drug delivery, targeted drug delivery systems (DDS) for colon delivery, anticancer DDS targeted to colon cancer are examined. Directions of future development are discussed.
Collapse
Affiliation(s)
- Tamara Minko
- Department of Pharmaceutics, Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA.
| |
Collapse
|